Fu Zhifeng, Song Jitao, Pi Yilin, Sun Xianxin, Liu Maoning, Xiao Zunlong, Chen Jing
Department of Gastroenterology, Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Nangang District, Harbin, 150086, Heilongjiang Province, China.
Dig Dis Sci. 2023 Apr;68(4):1574-1584. doi: 10.1007/s10620-022-07649-8. Epub 2022 Aug 22.
Pancreatitis is the most common complication of post-endoscopic retrograde cholangiopancreatography (ERCP). There are currently no prediction models, particularly for post-ERCP pancreatitis (PEP) after biliary stent placement due to malignant biliary obstruction (MBO). To that end, we aim to develop and validate a predictive model for PEP.
We retrospectively analyzed the data of patients who underwent ERCP for biliary stent placement due to MBO at the Second Affiliated Hospital of Harbin Medical University from January 1, 2014 to August 31, 2021. The eligible patients were randomly allocated to the development and validation cohorts. A prediction model was built using the development cohort, and the model's effect was validated using a validation cohort.
A total of 1524 patients were enrolled, including 1016 in the development cohort and 508 in the validation cohort, with an overall PEP rate of 7.1%. The model's predictors included acute pancreatitis history, the absence of pancreatic duct dilation, nonpancreatic cancer, difficult cannulation, and pancreatic injection. The area under the curve (AUC) in the development cohort was 0.810, and the incidence of PEP in the low-risk, medium-risk, and high-risk groups was 1.53%, 9.12%, and 36.36%, respectively. Meanwhile, the AUC of the validation cohort was 0.781, and the incidence of PEP in the low-risk, medium-risk, and high-risk groups was 4.17%, 8.75%, and 41.67%, respectively.
This study was the first to build and validate a risk prediction model, especially for PEP after biliary stent placement due to MBO. Moreover, this model might assist clinicians in identifying high-risk patients and help implement preventive measures in a more timely manner.
胰腺炎是内镜逆行胰胆管造影术(ERCP)后最常见的并发症。目前尚无预测模型,尤其是针对恶性胆管梗阻(MBO)导致的胆管支架置入术后的ERCP后胰腺炎(PEP)。为此,我们旨在开发并验证一种PEP预测模型。
我们回顾性分析了2014年1月1日至2021年8月31日在哈尔滨医科大学附属第二医院因MBO行胆管支架置入术的患者数据。符合条件的患者被随机分配到开发队列和验证队列。使用开发队列建立预测模型,并使用验证队列验证模型效果。
共纳入1524例患者,其中开发队列1016例,验证队列508例,总体PEP发生率为7.1%。该模型的预测因素包括急性胰腺炎病史、胰管未扩张、非胰腺癌、插管困难和胰腺注射。开发队列中的曲线下面积(AUC)为0.810,低风险、中风险和高风险组的PEP发生率分别为1.53%、9.12%和36.36%。同时,验证队列的AUC为0.781,低风险、中风险和高风险组的PEP发生率分别为4.17%、8.75%和41.67%。
本研究首次建立并验证了风险预测模型,尤其是针对MBO导致的胆管支架置入术后的PEP。此外,该模型可能有助于临床医生识别高危患者,并有助于更及时地采取预防措施。